Time for More Inclusive Cancer Trials

Authors: Piet Dirix MD, PhD, Lynda Wyld MD, PhD, Shani Paluch-Shimon MBBS, MSc and Philip Poortmans MD, PhD
View More View Less
Restricted access

Disclosures: The authors have disclosed that they have no financial interests, arrangement affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.

Correspondence: Philip Poortmans, MD, PhD, Oosterveldlaan 24, 2610 Wilrijk, Belgium. Email: Philip.poortmans@telenet.be

View associated content

  • 1.

    Abi Jaoude J, Kouzy R, Lin TA, Performance status restriction in phase III cancer clinical trials. J Natl Compr Canc Netw 2020;18:13221326.

    • Search Google Scholar
    • Export Citation
  • 2.

    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:27202726.

  • 3.

    Freedman RA, Foster JC, Seisler DK, Accrual of older patients with breast cancer to alliance systemic therapy trials over time: Protocol A151527. J Clin Oncol 2017;35:421431.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 2005;365:8293.

  • 5.

    Santacatterina M, Bottai M. Inferences and conjectures in clinical trials: a systematic review of generalizability of study findings. J Intern Med 2016;279:123126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Chow R, Bruera E, Temel JS, Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis. Support Care Cancer 2020;28:20712078.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Cheng S, Qureshi M, Pullenayegum E, Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. ESMO Open 2017;2:e000225.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Denduluri N, Pratt DA, Wang Y, Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr Canc Netw 2015;13:13831393.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    US Food & Drug Administration. FDA-ASCO public workshop: 2019 clinical outcome assessments in cancer clinical trials fourth annual workshzCop. Accessed September 4, 2020. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-asco-public-workshop-2019-clinical-outcome-assessments-cancer-clinical-trials

    • Export Citation
  • 10.

    Rattray NJW, Trivedi DK, Xu Y, Metabolic dysregulation in vitamin E and carnitine shuttle energy mechanisms associate with human frailty. Nat Commun 2019;10:5027.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 300 300 300
PDF Downloads 60 60 60
EPUB Downloads 0 0 0